September 5, 2025,  U.S. Food and Drug Administration (FDA) has issued Import Alert #66-80, titled:

“Detention Without Physical Examination of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Bulk Drug Substances”

This action means that semaglutide, tirzepatide, and other GLP-1 receptor agonist APIs from foreign sources are now subject to automatic detention at U.S. ports of entry, unless the manufacturer is listed on the FDA’s Green List.

❗ Why This Matters

GLP-1 receptor agonists (like semaglutide and tirzepatide) are widely used in the treatment of type 2 diabetes and chronic weight management. Due to shortages of approved products, many compounders turned to foreign API sources—but FDA investigations have found serious compliance issues:

• 21% of API manufacturing sites reviewed were found noncompliant with U.S. current Good Manufacturing Practices (cGMPs).
• Several firms refused to provide FDA-requested documentation or quickly deregistered after offering APIs for sale.
• FDA has raised concerns about product adulteration, lack of GMP controls, and inconsistent quality in compounded products using these APIs.

⚠️ What’s the Impact?

• Automatic detention (DWPE): Products not from FDA-approved sources will be held at the border without physical inspection.
• Supply chain disruption: Manufacturers, importers, and distributors of GLP-1 APIs may face delays, rejections, or enforcement actions.
• Reputation risk: Firms associated with noncompliant suppliers may experience market confidence issues or face scrutiny in future regulatory reviews.

🛡️ How EZFDA Can Help

At EZFDA, we specialize in helping companies navigate the complexities of FDA compliance and enforcement. Our team provides:

• Regulatory strategy & risk assessment for GLP-1 APIs
• Review of API supplier compliance history
• FDA communication support and documentation preparation
• Strategic guidance to maintain uninterrupted U.S. market access

📩 Get in touch: info@ezfda.com
🌐 Contact us: www.ezfda.com/contact

Let EZFDA be your partner in navigating this critical regulatory change.